Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QPI-1007 in Acute Primary Angle-Closure Glaucoma
NCT01965106Phase 2Completed
- Sponsor
- Quark Pharmaceuticals
- Start
- Dec 2013
- Primary completion
- Jun 2015
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 3
01
Overview
A Phase 2 trial of QPI-1007 in Acute Primary Angle Closure Glaucoma (APACG), sponsored by Quark Pharmaceuticals. Started Dec 2013; status: completed.
02
Drugs
QPI-1007
03
Conditions
Acute Primary Angle Closure Glaucoma (APACG)
Beyond the preview
Go deeper on NCT01965106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01965106.